ArticleJournal of cardiothoracic surgery2026
Protective mechanism of nicorandil on myocardial ischemia-reperfusion injury: a multi-omics study highlighting CYP4F5 as a key node.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNicorandil, a vasodilator, exhibits potential in improving myocardial blood supply, but its protective mechanism against myocardial ischemia-reperfusion (I/R) injury remains unclear. This study aims to explore the cardioprotective effects of nicorandil on myocardial I/R injury and elucidate its molecular mechanisms, providing a theoretical basis for clinical treatment.
methodsMyocardial I/R injury models were established using SPF-grade male Sprague-Dawley (SD) rats, randomly divided into control, I/R, and I/R+Nicorandil groups (n = 6 per group). The I/R+Nicorandil group, nicorandil (5 mg/kg) was injected intraperitoneally every day from 3 days before the establishment of myocardial I/R model. Myocardial injury was assessed through TTC staining, hematoxylin-eosin (HE) staining, and multi-omics analyses (transcriptome sequencing, proteomics, and metabolomics) to investigate alterations at genetic, protein, and metabolite levels.
resultsBiochemical and histological analyses revealed that nicorandil significantly reduced serum levels of lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and creatine kinase (CK), while decreasing myocardial infarction area and pathological damage. Transcriptome sequencing identified differentially expressed genes (DEGs) enriched in TNF and chemokine signaling pathways between control vs. I/R and I/R vs. I/R+Nicorandil groups. Proteomics analysis screened differentially expressed proteins (DEPs) primarily involved in glycolysis and protein glycosylation. Metabolomics detected two key differential metabolites in positive ion mode. Multi-omics integrative analysis identified CYP4F5 as a pivotal protein node, showing significant correlations with multiple metabolites. Western blot results demonstrated that nicorandil modulated the expression of PPAR-α, NF-κB, cGAS, and STING pathway proteins in myocardial I/R injury.
conclusionNicorandil may alleviate myocardial I/R injury by regulating CYP4F5-associated metabolites and signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.